Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis

Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease

“…Our data might suggest a protective effect of statins in NAFLD, as reported in other studies on patients taking statins for cardiometabolc disorders [37,38].…”

Non-alcoholic fatty liver disease: an emerging driving force in chronic kidney disease

“…Statins can be safely used for dyslipidemia in patients with NAFLD/NASH. Recent post-hoc analyses of randomized controlled trials have also suggested that the cardioprotective effect of statins is more pronounced among CVD patients with mild-to-moderate baseline elevations in serum aminotransferase levels 125,126 . Statins are safe and may also reduce CVD events and mortality in patients with NAFLD.…”

Nonalcoholic fatty liver disease and cardiovascular risk

“…Evidence that cholesterol lowering with statins reduces cardiovascular risk comes from the Greek Atorvastatin and Coronary Heart Disease Evaluation study, in which atorvastatin reduced the incidence of new cardiovascular events to a greater extent in patients with NAFLD (assumed by raised liver enzymes) than among those with normal liver enzymes [28] . Patients without serum cholesterol elevation benefited as well, and there was a 40% reduction in serum triglyceride.…”